Pharma results · Natural delivery · Ignyt bioactive peptide technology
Peer-reviewed research, independent trials and global recognition supporting the bioactive ingredients used in Ignyt products.
Peer-reviewed research
More than a decade of independent research examining the core ProGo® bioactive ingredient used in Ignyt products.
+140% ferritin (restored to normal); +14% hemoglobin vs. +2% in the whey group (p<0.05). Basis for six FDA structure/function claims and Health Canada qualified claims.
View study ↗−5.9% BMI (p<0.05); significant changes in four metabolism-relevant serum biomarkers; consistent 3–6% reduction in fasting blood glucose.
View study ↗+10.24% perceived energy; −9% oxidative stress; HMOX1 ↑4.09×; FTH1 ↑3.77×; skin, hair and nail measures +24%; IL-5, IL-8 and CRP reduced.
View study ↗ProGo® reached peak blood leucine 15 minutes faster than WPC-80, with rapid aminoacidemia and a comparable insulin response.
View study ↗The smallest ProGo® peptide fraction activated GLP-1 and GIP receptors, supported pancreatic islet cell protection, inhibited DPP-IV and improved glucose uptake into muscle.
View study ↗ProGo® significantly reduced colon tissue injury, inflammatory cell infiltrates and oxidative stress. HMOX1 upregulation was also observed.
View study ↗ProGo® peptides demonstrated DPP-IV inhibition and improved glucose uptake into muscle, findings relevant to insulin action and metabolic health research.
View study ↗ProGo® upregulated 16 oxidative protective genes and downregulated nine oxidative stress genes. FTH1, HMOX1 and ALOX12 showed notable fold-change.
View study ↗In the press
Trade, financial and industry reporting covering the research, agreements and momentum behind ProGo® and Fission Holdings.
The agreement grants Fission Holdings worldwide rights to market and sell ProGo® in the affiliate and network-marketing channel.
Read coverage ↗Coverage of the published ProGo® receptor-activation research.
Read coverage ↗Coverage of the 128-day energy, oxidative stress, skin, hair and nail outcomes study.
Read coverage ↗Industry coverage from SupplySide West.
Read coverage ↗A whitepaper announcement covering GLP-1/GIP activation, myostatin inhibition and anti-inflammatory bioactivity.
Read coverage ↗Regulatory recognition
ProGo® has received an FDA New Dietary Ingredient acknowledgement and has associated structure/function and qualified health claims in North America.
“Supports healthy ferritin and hemoglobin levels.”
“Helps maintain iron-rich blood.”
“Promotes energy utilization.”
“Supports red blood cell production.”
“Supports gastrointestinal and immune system health.”
“Assists in iron absorption from your daily diet.”
“Helps with dry skin.”
“Reduces wrinkles and promotes skin smoothness.”
“Prevents an increase in trans-epidermal water loss.”
“Supports skin health and appearance.”
“Reduces occasional fatigue and general feelings of occasional tiredness.”
“Reduces oxidative stress caused by free radicals.”
“Acts as an antioxidant.”
“Helps maintain healthy levels of ferritin and hemoglobin.”
“Helps maintain healthy levels of blood components required for oxygen transport.”
“Provides antioxidants for the maintenance of good health.”
“Helps promote healthy skin.”
These claims apply specifically to ProGo® bioactive peptides as manufactured and supplied by Hofseth BioCare ASA. Structure/function claims are subject to 21 CFR 101.93. Health Canada qualified health claims are regulated under the Natural Health Products Regulations.
More than $50 million invested, a decade of published research and distribution across 80+ countries.
Partnerships & endorsements
Ingredient supply, clinical research and channel partnerships supporting the science behind Ignyt.
Fission Holdings LLC holds the worldwide exclusive rights to import, market, distribute and sell HBC's ProGo® ingredient within this channel, under the agreement announced by Hofseth BioCare ASA on May 22, 2026.
View official announcement ↗Holds exclusive worldwide rights to distribute ProGo® in the affiliate and network-marketing channel and supports Ignyt distribution.
Source and manufacturer of ProGo®, a patented salmon-derived bioactive peptide made from sustainable Norwegian Atlantic salmon offcuts.
Researchers published the gut-health study in Biomolecules in 2022, reporting immunomodulatory activity and HMOX1 upregulation.
Conducted the 128-day vitality, inflammation and cosmetic-outcomes trial published in 2024.
Strategic partnership focused on performance products using ProGo®, OmeGo® and CalGo® ingredients.